Search 

Albumedix is a science-driven, biotechnology company focused on enabling the creation of superior biopharmaceuticals utilizing our recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and unstable drug candidates reach patients worldwide. We are proud to be recognized as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical companies worldwide. We are headquartered in Nottingham, England with approximately 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started 30 years ago.

ApconiX was formed by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company known for its expertise in nonclinical safety toxicology and ion channel electrophysiology.  The company is founded on the skills and experience of a growing team with a wide range of expertise in preclinical drug safety.

The model for the pharmaceutical industry has evolved in recent years with large pharma reducing internal capability and outsourcing key skills to trusted partners.  There are many more SMEs who also need access to specialised services.

ApconiX addresses both needs by providing an exceptional group of scientists to these companies, in a cost-effective and flexible way.  In this way, companies work with people they trust, to make better decisions on drug safety.

The market need has been demonstrated by the remarkable growth of ApconiX. The current client list is spread across the globe.
ApconiX has embarked on several strategic international alliances.  In collaborating with the French company PhysioStim, ApconiX has become part of a European centre of excellence for preclinical cardiovascular safety evaluation.  

ApconiX is continually forming collaborative relationships, helping customers large and small. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate the difficult pathway towards safe, effective and profitable drugs.

Aptus Clinical is a clinical research provider formed by three former AstraZeneca colleagues who have over 75 years’ combined drug development experience.



Our mission is to be the partner of choice for biopharmaceutical companies and academic researchers, supporting them in their quest to develop new and valued medicines. We understand the challenges faced by our clients and will provide key insight and experience to meet the needs of our customers by delivering operational excellence in order to achieve the exacting standards of the industry

 

With experience ranging from early methodology studies and first time in man, through proof of concept to Phase III registration and clinical pharmacology studies this  breadth and depth of knowledge is at the disposal of our customers.



We recognise that the increasing legislative, regulatory, ethical and patient focused expectations being placed on the conduct of clinical studies, is making their successful conduct and delivery ever more costly and difficult to achieve.



With this in mind, Aptus Clinical is continually developing a team of highly experienced clinical research experts who have extensive insight into the effective delivery of studies and are passionate about partnering with biotechs, pharma and academia to provide bespoke clinical delivery solutions.



Whether you are a company or academic institution looking for strategic input to study designs or need access to flexible, cost effective and experienced clinical research resources to deliver high quality studies, then please get in touch.

Arecor is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

Established in 1989, the BIA (BioIndustry Association) exists to encourage and promote a financially sound and thriving bioscience sector within the UK economy and concentrates its efforts on emerging enterprise and the related interests of companies with whom such enterprise trades.



With over 300 members, the BIA supports a wide range of sectors, majoring on the human health benefits of the technology and represents the interests of these innovative companies to a broad section of stakeholders from patient groups to politicians, advancing its members interests both within the UK and internationally to create a healthy UK bioscience sector which benefits society.

BioPartner UK leads the UK Delegation to several partnering conferences each year. It is a UK Accredited Trade Organisation facilitating international partnering for trade, investment and collaborations with Life Sciences organisations across the UK. BioPartner is a membership organisation, supporting UK SMEs and startups, and signposting organisations worldwide to UK expertise.

BioPartner has alliances with organisers of international biopartnering events, and with UK membership organisations, operating both independently and in partnership with the UK government. BioPartner disseminates tradeshow access grants to help UK-based SMEs exhibit their services and products in new overseas markets.

bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

Crescendo Biologics is a biopharmaceutical company developing conditionally-activated T cell enhancing therapeutics, with a particular focus on CD137 (4-1BB).

The innovative, first and best in class programmes are designed to activate only tumour-specific T cells in the tumour micro-environment and not outside it. This approach is expected to reduce the toxicities experienced with traditional immunotherapies and also to lead to the proliferation of tumour-specific T cells with a broad, long-lasting anti-tumour response.

Our lead programme, CB307, is a CD137 (4-1BB) x PSMA bispecific for PSMA-positive tumours. CB307’s unique format delivers highly potent tumour-specific killing, while avoiding systemic toxicity and can be applied to a broad range of PSMA-positive cancer indications.

Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® platform, which generates fully human VH domains (Humabodies). Humabodies are matured in vivo in the absence of any light-chains and are robust and stable molecules. Humabody VH domains can be easily assembled into multi-specific formats which can access novel biology and deliver superior tumour accumulation and penetration compared to conventional monoclonal antibody-based approaches.

The Humabody platform has received third party validation through its strategic, multi-target collaboration in immuno-oncology, ADCs and CAR-Ts with Takeda, worth up to $790M, and from licensing its first programme for an inflammatory target to Zai Lab in 2018. In 2020 Crescendo entered into a Clinical Development Partnership with Cancer Research UK to progress CB213, a PD-1 x LAG-3 bispecific, into the clinic.

Crescendo is progressing novel Humabody®-based product opportunities, through in-house development and strategic collaborations as well as seeking strategic partners to develop novel Humabody therapeutics leveraging our in-house expertise and our pipeline of Humabody molecules.

New technologies have the potential to transform healthcare and medical research by increasing efficiency and creating more personalised medicine.



Ctrl Group is a team of designers, researchers, software developers and healthcare experts who work internationally with healthcare companies and providers who want to use new technology to improve people’s health. We create products and services that are effective, engaging and safe.

The Department for International Trade (DIT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade.